Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in via AAO
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Browse by collection
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Browse by collection
Authors
About
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in via AAO
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 98, Issue Suppl 1
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
XML
Original article
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
Online download statistics by month:
Online download statistics by month: May 2014 to March 2024
Abstract
Full
Pdf
May 2014
280
125
140
Jun 2014
240
127
124
Jul 2014
234
73
99
Aug 2014
109
48
46
Sep 2014
114
50
48
Oct 2014
87
55
40
Nov 2014
53
54
30
Dec 2014
58
50
31
Jan 2015
44
34
27
Feb 2015
53
60
39
Mar 2015
53
49
17
Apr 2015
36
45
15
May 2015
41
32
23
Jun 2015
45
26
33
Jul 2015
51
30
26
Aug 2015
48
23
27
Sep 2015
44
24
24
Oct 2015
31
14
7
Nov 2015
42
27
35
Dec 2015
40
33
17
Jan 2016
43
36
26
Feb 2016
34
15
11
Mar 2016
29
36
22
Apr 2016
36
26
18
May 2016
37
20
10
Jun 2016
31
25
17
Jul 2016
34
17
24
Aug 2016
37
22
14
Sep 2016
36
21
17
Oct 2016
33
13
13
Nov 2016
27
29
18
Dec 2016
41
24
14
Jan 2017
43
19
10
Feb 2017
31
20
17
Mar 2017
34
54
31
Apr 2017
16
49
13
May 2017
16
49
16
Jun 2017
30
41
34
Jul 2017
61
42
28
Aug 2017
97
75
23
Sep 2017
114
98
18
Oct 2017
213
196
31
Nov 2017
133
99
15
Dec 2017
104
80
13
Jan 2018
111
81
25
Feb 2018
92
70
16
Mar 2018
104
75
12
Apr 2018
85
63
10
May 2018
88
76
29
Jun 2018
125
97
23
Jul 2018
165
121
45
Aug 2018
124
110
31
Sep 2018
133
109
17
Oct 2018
88
69
24
Nov 2018
99
77
25
Dec 2018
79
65
13
Jan 2019
97
77
40
Feb 2019
77
65
14
Mar 2019
84
84
16
Apr 2019
54
53
14
May 2019
78
78
23
Jun 2019
96
90
16
Jul 2019
123
123
20
Aug 2019
85
85
10
Sep 2019
81
81
14
Oct 2019
76
74
13
Nov 2019
71
71
12
Dec 2019
92
92
12
Jan 2020
84
81
12
Feb 2020
82
81
14
Mar 2020
100
100
11
Apr 2020
77
76
5
May 2020
91
90
14
Jun 2020
80
80
15
Jul 2020
85
85
11
Aug 2020
77
75
17
Sep 2020
93
91
17
Oct 2020
95
95
25
Nov 2020
50
49
16
Dec 2020
66
57
15
Jan 2021
43
43
12
Feb 2021
49
49
12
Mar 2021
66
66
10
Apr 2021
65
65
15
May 2021
51
51
11
Jun 2021
66
65
19
Jul 2021
42
42
12
Aug 2021
41
43
13
Sep 2021
61
61
16
Oct 2021
65
65
27
Nov 2021
59
59
28
Dec 2021
56
56
14
Jan 2022
47
50
7
Feb 2022
72
60
18
Mar 2022
56
51
11
Apr 2022
77
53
29
May 2022
82
72
27
Jun 2022
78
67
16
Jul 2022
53
55
14
Aug 2022
102
98
13
Sep 2022
82
73
49
Oct 2022
85
74
20
Nov 2022
100
69
17
Dec 2022
47
39
4
Jan 2023
54
47
12
Feb 2023
78
70
14
Mar 2023
75
58
15
Apr 2023
56
34
16
May 2023
64
42
20
Jun 2023
52
39
10
Jul 2023
47
32
18
Aug 2023
55
39
11
Sep 2023
63
30
13
Oct 2023
45
22
7
Nov 2023
65
27
6
Dec 2023
32
28
21
Jan 2024
27
27
16
Feb 2024
39
29
25
Mar 2024
59
37
20
Total
8656
7018
2585
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in via AAO
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF